Wells Fargo & Company Vera Therapeutics, Inc. Call Options Transaction History
Wells Fargo & Company
- $407 Billion
- Q2 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding VERA
# of Institutions
181Shares Held
55MCall Options Held
42.2KPut Options Held
114K-
Avoro Capital Advisors LLC New York, NY4.31MShares$211 Million2.13% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD3.62MShares$178 Million0.02% of portfolio
-
Black Rock Inc. New York, NY3.34MShares$164 Million0.0% of portfolio
-
Abingworth LLP London, X02.96MShares$145 Million19.0% of portfolio
-
Sofinnova Investments, Inc. Menlo Park, CA2.79MShares$137 Million5.61% of portfolio
About Vera Therapeutics, Inc.
- Ticker VERA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 27,042,300
- Market Cap $1.33B
- Description
- Vera Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases in the United States. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase IIb clinical trial for patients with ...